Nitric Oxide Synthase Inhibition Prevents Cell Proliferation in Glioblastoma
Daniel Kruglyakov1, Shashank Kumar Ojha1, Maryam Kartawy1
1Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Abstract:
Glioblastoma multiforme (GBM) is a prevalent and aggressive primary brain tumor, presenting substantial treatment challenges and high relapse rates. GBM is characterized by alterations in molecular signaling and enzyme expression within malignant cells. This tumor exhibits elevated nitric oxide (NO.) levels. NO. is a crucial signaling molecule involved in the regulation of neuronal functions, synaptic transmission, and cell proliferation. It is primarily synthesized from L-arginine by nitric oxide synthase (NOS) enzymes. The increased levels of NO. in GBM stem from dysregulated activity and expression of clinically relevant NOS isoforms, particularly inducible NOS (iNOS) and neuronal NOS (nNOS). Based on this knowledge, we hypothesize that targeted pharmacological intervention with N6-(1-iminoethyl)-L-lysine (L-NIL), an iNOS inhibitor, and 7-Nitroindazole (7-NI), an nNOS inhibitor, may suggest a promising therapeutic strategy for the treatment of GBM. To test our hypothesis, we utilized the U87-MG cell line as an in vitro model of GBM. Our results showed that treatment with L-NIL and 7-NI led to a reduction in NO. levels, NOS activity, and clonogenic proliferation in U87-MG cells. These findings suggest that NO. and NOS enzymes might be prospective therapeutic targets for GBM.
Insights
Targeting nitric oxide (NO) and its producing enzymes, nitric oxide synthase (NOS), with inhibitors L-NIL and 7-NI, reduced GBM cell proliferation. This suggests NO and NOS are potential therapeutic targets for glioblastoma multiforme (GBM).
Area of Science:
- Neuroscience
- Oncology
- Biochemistry
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain tumor with high relapse rates.
- Elevated nitric oxide (NO) levels and dysregulated nitric oxide synthase (NOS) activity, particularly inducible NOS (iNOS) and neuronal NOS (nNOS), are observed in GBM.
- NO is a key signaling molecule implicated in cell proliferation and neuronal functions.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting iNOS and nNOS in GBM.
- To test the hypothesis that pharmacological intervention with iNOS and nNOS inhibitors can impede GBM progression.
Main Methods:
- Utilized the U87-MG cell line as an in vitro model for GBM.
- Administered N6-(1-iminoethyl)-L-lysine (L-NIL), an iNOS inhibitor, and 7-Nitroindazole (7-NI), an nNOS inhibitor.
- Assessed the impact of L-NIL and 7-NI on NO levels, NOS activity, and cell proliferation.
Main Results:
- Treatment with L-NIL and 7-NI significantly reduced NO levels in U87-MG cells.
- Inhibitor treatment led to decreased NOS activity within the GBM cell model.
- L-NIL and 7-NI demonstrated a reduction in the clonogenic proliferation of U87-MG cells.
Conclusions:
- NO and NOS enzymes represent promising therapeutic targets for glioblastoma multiforme.
- Targeted inhibition of iNOS and nNOS may offer a novel strategy for GBM treatment.
- Further research into NO-modulating therapies for GBM is warranted.
More Related Videos
08:32Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
09:26Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
02:34Inhibition of Cdk Activity